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Purpose. To evaluate the long-term efficacy and safety of the iStent inject device (Glaukos Corporation, LagunaHills, CA) combined
with phacoemulsification in patients with coexistent cataract and open-angle glaucoma or ocular hypertension (OHT).Methods. A
prospective, uncontrolled, nonrandomized, interventional case series study was conducted in patients with both mild or moderate
open-angle glaucoma or OHT and cataract. Patients underwent cataract surgery along with the implant of two iStent inject devices.
Outcome measures were intraocular pressure (IOP), topical hypotensive medications required, and best-corrected visual acuity
(BCVA). Results. 20 patients were enrolled. Mean follow-up was 47.4 ± 18.46months. Mean baseline IOP was 19.95 ± 3.71mmHg
withmedication and 26±3.11mmHg afterwashout.Mean end-follow-up IOPwas 16.25±1.99mmHg, representing an IOPdecrease
of 36.92%, 9.74 ± 3.14mmHg (𝑃 < 0.001), from baseline washout IOP.Themean number of medications was significantly reduced
from 1.3 ± 0.66 to 0.75 ± 0.79 (𝑃 = 0.017). 45% of patients were medication-free by the end of follow-up. Mean logMAR BCVA
improved significantly from 0.42 ± 0.16 to 0.18 ± 0.16 (𝑃 < 0.001). No complications of surgery were observed. Conclusion. The
iStent inject device combined with cataract surgery served to significantly reduce both IOP and medication use in the long term in
patients with coexistent open-angle glaucoma or ocular hypertension (OHT) and cataract.
1. Introduction
Glaucoma is the leading cause of irreversible blindnessworld-
wide and is estimated to currently affect more than 60 mil-
lion people [1]. Elevated intraocular pressure (IOP) is the
main risk factor for the onset and advance of glaucoma. In
effect, reducing IOP is the accepted consensus strategy to
delay or even avoid the development of glaucoma and to
manage its progression [2].Thus, the ideal treatment for glau-
coma should offer continuous IOP management along with a
favourable safety profile.
Filtration surgery is usually performed in moderate or
advanced cases but is linked to complications [3] includ-
ing visual loss, bleb leak, inflammation, hypotony, and
endophthalmitis [4]. Microinvasive glaucoma surgery tries
to preserve conjunctival tissue of scarring through an ab
Hindawi Publishing Corporation
Journal of Ophthalmology
Volume 2016, Article ID 1056573, 7 pages
http://dx.doi.org/10.1155/2016/1056573
2 Journal of Ophthalmology
interno microincisional approach, with efficacy, high safety
profile, and fast recovery in mild-to-moderate glaucoma [5].
The iStent Trabecular Micro-Bypass (Glaukos Corporation,
Laguna Hills, CA, USA) bypasses the trabecular meshwork
(TM), which is the major source of resistance to outflow in
open-angle glaucoma. iStent has been successfully employed
to increase outflow in human anterior segments in vitro [6]
and in glaucoma patients [7].
The first-generation iStent, Model GTS-100, is a titanium
L-shaped stent that has proved safe and effective in lowering
IOP in patientswithmild-to-moderate glaucoma [7–10], even
in the long term [11]. This device has also been described to
achieve an IOP reduction to less than 15 mmHg if twoormore
iStent devices are implanted during cataract surgery [12].
A second-generation newmicroscale stent recently devel-
oped, the iStent inject Trabecular Micro-Bypass Model GTS-
400, also increased outflow facility in cultured human ante-
rior eye segments [13]. So far, three case series have revealed
the safety and efficacy of the iStent inject device [14–16].
Another randomized study compared outcomes of two iStent
inject devices versus two ocular hypotensive agents [17],
showing that the use of iStent inject device is at least as
effective as two medications. However, the follow-up of these
studies was no longer than 12 months.
The purpose of our study was to assess the long-
term efficacy and safety of implanting of two iStent inject
Model GTS-400 stents combined with phacoemulsification
in patients with coexistent cataract and open-angle glaucoma
or ocular hypertension (OHT). This study is a continuation
of our initial work [14], in which we reported outcomes one
year after iStent inject device placement inserted via first-
generation prototype G2-0 injectors.
2. Methods
Twenty patients with cataract and primary open-angle and
pseudoexfoliative glaucoma or OHT were enrolled for this
prospective, noncomparative, uncontrolled, nonrandomized,
intervention study.
The study protocol adhered to the tenets of the Declara-
tion of Helsinki and Spanish legislation and was approved by
our Institutional Review Board. Before recruitment, written
legally binding informed consent for Glaukos iStent inject
implantation and cataract surgery was obtained from each
patient.
Detailed subject inclusion criteria and surgical technique
were previously described [14]. The main inclusion criteria
were a previous diagnosis of mild-to-moderate open-angle
glaucoma (including pseudoexfoliative glaucoma) or OHT
and an IOP of 14–30mmHg as measured at the last two con-
secutive visits if receiving ocular hypotensive medications,
of 22–30mmHg if not, or of 22–32mmHg after hypotensive
drops washout.
Before surgery, all the patients receiving ocular hypoten-
sive medications were instructed to discontinue their use to
obtain baseline IOP measurements. All surgical procedures
were performed by two of the authors (JMMC and JGF), both
with similar experience in MIGS surgery. Surgical technique
is similar to that described for the GTS-100 device [13, 14].
After phacoemulsification and IOL placement, two GTS-
400 iStent devices were implanted through the clear corneal
incision (approximately 2.85mm) placed for phacoemul-
sification. First-generation prototype G2-0 injectors were
used to deliver the stents. Antiglaucoma topical therapy was
introduced postoperatively if the desired target IOP range, as
judged by the investigator, was not achieved.
Postoperative visits were scheduled for 1 day, 1 week, 1,
3, and 6 months, and 1, 2, 3, 4, 5, and 6 years after surgery.
Every visit included slit-lamp biomicroscopy, applanation
tonometer (Clement Clarke Perkins MK2 Tonometer) IOP
measurement, number of glaucoma medications, and BCVA.
Preoperatively and one month, three months, and every year
postoperatively, the nasal angle was examined by gonioscopy.
2.1. Data Analysis. Efficacy outcome measures were IOP and
topical ocular hypotensive medications used pre- and post-
operatively. Successful treatment was defined as an IOP
reduction ≥ 20% regardless of medication. We also defined
“complete success” as an IOP ≤ 18mmHg without postopera-
tive medication and “qualified success” as an IOP ≤ 18mmHg
with medication [18]. These outcomes were determined by
proportional analysis. Kaplan-Meier graphswere constructed
to estimate surgical success according to those success crite-
ria.
Failure rate included those patients who did not meet
success criteria, required further glaucoma surgery, or had
severe visual loss secondary to surgery itself.
Safety outcome measures were complications and log
MAR BCVA.
For a descriptive statistical analysis, we used Excel 2007
(Microsoft Corp.) with SPSS software (version 15.0, SPSS
Inc.). Results are provided as the mean ± standard deviation
(SD).
The Kolmogorov-Smirnov test was used to check the
normal distribution of data. A paired-sample t-test was used
to compare outcomes in the study group. Significance was set
at 𝑃 ≤ 0.05.
3. Results
Combined surgery was uneventful in all the participating
patients and the iStent was successfully implanted in all eyes,
although three patients received just one iStent for logistic
reasons. Postoperatively, gonioscopy revealed the presence of
only one iStent in a further four patients (20%). So, in seven
patients (35%), only one iStent was confirmed as functional.
Both groups were comparable in baseline IOP andmeds data,
because no significant differences were obtained at that time
point.
3.1. Patient Demographics. Twenty Caucasian subjects (11
women) were enrolled in the study, eight of whom had
primary open-angle glaucoma, eight had OHT, and four had
pseudoexfoliative glaucoma.
Mean follow-up was 47.4 ± 18.46 months (range 12–72
months) and median follow-up was 60 months. Eleven of the
patients completed at least five years of follow-up, and two of
them were followed six years (Table 1). Nine patients did not
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Table 1: Postoperative follow-up of 20 patients (n: number of patients).
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Figure 1: Mean intraocular pressure (IOP) (±standard error of the
mean) recorded at each follow-up visit (baseline IOP is medicated
IOP).
complete five years visit, due to logistic reasons (𝑛 = 4) and
mortality (𝑛 = 5).
3.2. IOP Results. Mean IOP with medication at baseline was
19.95 ± 3.71mmHg and after washout was 26 ± 3.11mmHg
(Figure 1). At the end of follow-up, mean IOP was 16.25 ±
1.99mmHg. The IOP decrease from preoperative washout
IOP was 9.74 ± 3.14mmHg, representing a significant
decrease of 36.92% (𝑃 < 0.001). The mean IOP drop relative
to preoperative IOP with medication was 3.7 ± 3.7mmHg,
representing a 16.49% decrease (𝑃 < 0.001). Figure 2 shows
preoperative IOP and final IOP without and with medication
in each patient via scatter plot (Figure 2).
In the 11 patients completing at least five years of follow-
up, mean IOP with medication at baseline was 20.36 ±
4.57mmHg and after washout was 25.7 ± 3.06mmHg. End-
follow-up mean IOP was 16.18 ± 2.27mmHg. Reductions in
IOP from preoperative washout IOP and from preoperative
IOP with meds (9.5 ± 3.1mmHg and 4.18 ± 4.62mmHg;
36.56% and 17.52%; 𝑃 < 0.001 and 𝑃 = 0.013, resp.) recorded
in this subset of 11 eyes were similar to the reduction observed
for the entire set of 20 eyes.
Subanalysis of IOP results depending of the number of
functional iStent devices showed no significant differences
in final IOP decrease between one and two functional iStent
devices (𝑃 = 0.425). However, the group with two iStent
devices had an IOP decrease of 10.42 ± 3.6mmHg versus
8.57 ± 1.81mmHg in the one functioning iStent group.
Three eyes (15%) showed transient IOP elevation to above
30mmHg one day postoperatively. We previously attributed
this to retained viscoelastic and observed its resolution by the
one-week visit [14]. There were no additional reports of IOP
elevation during the remaining course of long-term follow-
up.
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Figure 2: Scatter plot representing preoperative intraocular pres-
sure (IOP) after washout and postoperative IOP without and with
meds. Continuous line represents regression line (R2 = 0.098).
Discontinuous line represents IOP of 18mmHg, defined as success
in the study.
Table 2: Number of antiglaucomamedications used at baseline and
final follow-up.
Follow-up time None drops One drop Two drops
Baseline 2 (10%) 10 (50%) 8 (40%)
Final 9 (45%) 7 (35%) 4 (20%)
3.3. AntiglaucomaMedications. Themajority of subjects red-
uced their medication burden during the course of follow-
up. Before surgery, the mean number of glaucoma med-
ications was 1.3 ± 0.66 (Figure 3). At the end of follow-
up, the mean number of medications decreased to 0.75 ±
0.79, representing a significant mean reduction in glaucoma
medications of 0.5 ± 0.89 (𝑃 = 0.017). Table 2 shows the
proportion and number of patients receiving no, one, or two
medications at baseline and at the final of follow-up.
At one year, 15 patients (75%) required no topical therapy,
while just one subject (5%) needed two antiglaucomamedica-
tions. At the 3-year visit, seven of the 13 patients (53.9%) who
completed the three years of follow-up were using one or two
medications, while six patients weremedication-free (46.2%).
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Table 3: Success rates recorded during follow-up (w/o: without).
Follow-up time IOP reduction ≥ 20% Complete success Qualified success
w/o meds with or w/o meds
1 month 63% 84% 55% 10%
3 months 84% 100% 65% 15%
6 months 73% 94% 50% 15%
1 year 73% 100% 50% 20%
2 years 25% 62% 35% 41%
3 years 33% 86% 31% 46%
4 years 30% 80% 28% 36%
5 years 20% 100% 28% 64%
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Figure 3: Use of glaucoma medications at each follow-up visit.
At five years, three patients (27.3%) were medication-free;
four patients (36.4%) were taking one medication, while four
patients (36.4%) were using two antiglaucoma drops. In the
11 eyes with 5-year follow-up data, the number of subjects
on two medications translated to a nonsignificant glaucoma
medication reduction in that group of patients.
The mean number of medications administered preoper-
atively in the patients who completed five years of follow-up
was 1.18 ± 0.75. At the end of follow-up, this figure fell to
1.09 ± 0.83 medications, representing a mean reduction of
0.09 ± 0.94 (𝑃 = 0.756). At five years, three of the 11 patients
(27.3%) were free of medication.
Subanalysis of medication use results depending of the
number of functional iStent devices showed no significant
differences in the final mean number of glaucoma medi-
cations (𝑃 = 0.255). However, the group with two iStent
devices had a mean reduction of 0.77 ± 0.93meds versus
0.14 ± 0.9meds in the one functional iStent group. Besides,
the percentage of eyes not requiring antiglaucomatous med-
ications at the end of follow-up was higher in the group with
two functioning iStent devices (61.5%) than in the group with
one functioning iStent (14.3%).
3.4. Success Rate. At three years of follow-up, 33% of patients
achieved an unmedicated IOP reduction ≥ 20% versus
baseline unmedicated IOP, and 86% experienced an IOP
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Figure 4: Kaplan-Meier plot of the cumulative probability of success
defined as an IOP reduction ≥ 20% regardless of medication.
reduction ≥ 20% regardless of medication. At five years,
the percentage of patients showing an unmedicated IOP
reduction ≥ 20% versus baseline washout IOP was 20%,
while 100% experienced an IOP reduction ≥ 20% regardless
of medication. At this follow-up time, seven out of 11
patients (63.63%) showed an IOP ≤ 16mmHg regardless of
medication.
The cumulative probability of success defined as an IOP
reduction ≥ 20% using Kaplan-Meier survival analysis was
72.4% at two years and 64.4% at three years (Figure 4).
Complete success at the end of follow-up was recorded
in eight patients (40%) and qualified success in 10 of our 20
patients (50%). Similar rates were obtained for the subset of
patients completing five years of follow-up, though the com-
plete success rate was slightly lower and the qualified success
higher (Table 3). The cumulative probability of complete and
qualified success using Kaplan-Meier survival analysis at two
years was 10% and 35%, respectively (Figures 5 and 6).
By the end of follow-up, 15 of the 20 subjects (75%)
showed an IOP ≤ 16mmHg regardless of medication, includ-
ing six patients of the 20 (30%) requiring no medication.
No patient needed any further glaucoma surgery over the
follow-up period.
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Table 4: Outcome variables reported in the studies that have addressed the efficacy of iStent GTS-400 placement. The data provided for the
present study are end-follow-up data for the 20 eyes enrolled and 5-year results for 11 eyes.
Source n Combinedphaco
Follow-up
(months)
Mean IOP reduction
(mmHg) from preop
IOP ≤ 18mmHg
w/o meds Mean reduction in meds
Arriola-Villalobos et al. [14]∗ 20 Yes 12 3.2 ± 3.75 50% 1 ± 0.79
Voskanyan et al. [15] 92 No 12 22.1 ± 3.3 versus
15.7 ± 3.7
† 66% NA
Klamann et al. [16] 17 No 6 21.19 ± 2.56 versus
14.19 ± 1.38
† NA
2.19 ± 0.91 versus
0.88 ± 0.62
†
Fea et al. [17] 94 No 12 8.1 ± 2.6 92.6% NA
Present study∗ 20 Yes 47.4 ± 18.46 3.7 ± 3.7 40% 0.6 ± 0.88
11 60 4.18 ± 4.62 28% 0.09 ± 0.94
Preoperative IOP refers to medicated IOP. (n: number of patients; w/o: without; †data not available, mean preoperative versus mean postoperative data; ∗same
set of patients; NA: not available.)
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Figure 5: Kaplan-Meier plot of the cumulative probability of com-
plete success, defined as an IOP ≤ 18mmHg without postoperative
medication.
3.5. Safety Outcomes. No visual acuity loss was recorded;
logMAR BCVA significantly improved from amean of 0.42±
0.16 preoperatively to 0.18 ± 0.16 at the end of follow-up
(𝑃 < 0.001).
No adverse events related to iStent inject implantation
were reported. During the long-term follow-up, five patients
suffered an eye condition unrelated to iStent inject implanta-
tion. Three of these patients required Nd:YAG capsulotomy
due to posterior capsule opacification (PCO). One patient
(whohadOHTandhighmyopia) suffered retinal detachment
40 months after the initial surgery, with excellent visual
recovery after pars plana vitrectomy.The last of these patients
developed epiretinal membrane three years after the initial
procedure. However, no surgery was required due to the
patients’ lack of symptoms and good visual acuity.
4. Discussion
In this series of 20 patients, the implant of two iStent
inject devices using first-generation prototype G2-0 injectors
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Figure 6: Kaplan-Meier plot of the cumulative probability of
“qualified success,” defined as an IOP ≤ 18mmHg with medication.
combined with phacoemulsification led to a significant IOP
reduction (𝑃 < 0.001) and a significant decrease in the
number of antiglaucoma medications required (𝑃 = 0.017)
after a mean follow-up of almost four years. The subset
of 11 patients completing five years of follow-up showed a
similar significant IOP decrease (𝑃 < 0.001) along with
a nonsignificant decrease in the number of antiglaucoma
medications required (𝑃 = 0.756).
In both the full set of 20 eyes and the subset of 11
eyes, the IOP reduction from medicated preoperative IOP
was approximately 4mmHg. This decrease is higher than
the approximate 2mmHg decrease reported after cataract
surgery alone [19].
IOP reduction in this small patient cohort was not as
pronounced as that reported in the larger studies that have
addressed iStent inject implantation (Table 4) as a single pro-
cedure [15–17]. In all these studies, two iStent inject devices
were implanted per eye. This difference in outcome may be
attributed to shorter follow-up times. Our study outcomes
may have been affected by the fact that the patients in this trial
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were the first at our centre to receive an iStent inject device
such that surgeons were at the start of their learning curve.
Further, we used first-generation prototype G2-0 injectors in
all 20 patients in this series although a second-generation
injector (G2-M-IS) has since been introduced. This new
model is able to hold two stents so that the clinician can
insert two devices while entering the eye only once. This
improved injector design reduces the number of surgical
steps and thus raises the chances of more reliable surgery
and improved outcomes. Further, in our prior study, in a
large proportion of patients (7/20), only one functional stent
was observed on postsurgery gonioscopy [14]. It is likely that
these patients would have shown a greater IOP reduction if
two stents had been confirmed as functioning, based on in
vitro results indicating that that a second stent achieved a
further increase in outflow facility [4]. In effect, Belovay et
al. [12] observed the improved ability of multiple GTS-100
iStent devices to reduce IOP to below 15mmHg and reduce
topical ocular hypotensive medications. In fact, our subgroup
analysis, although not significant, showed higher decrease in
IOP and medication use at the end of the follow-up in the
group of two functioning iStent devices. These differences
could be significant with higher sample size.
In our patients, IOP was stable during follow-up
(Figure 1). The number of medications used increased over
time after the one-year visit (Figure 3). A slight increase in
the number of medications beyond one year of follow-up
was also reported in the long-term study in which one iStent
GTS-100 was implanted during phacoemulsification [11].
Notwithstanding, a discrete reduction was produced in the
number of antiglaucoma drops at five years, including three
patients (27.3%) who were medication-free. A recent report
has shown that the placement of two iStent GTS-400 devices
as a sole procedure is at least as effective as two medications
[17]. Reducing or eliminating the use of antiglaucoma drops
is highly desirable because the chronic use of antiglaucoma
drugs may lead to ocular surface damage and conjunctival
inflammation [20] or even reduce the success of subsequent
trabeculectomy [21].
Success in our study defined as an IOP reduction ≥ 20%
regardless of medication was achieved in all the patients at
the end of follow-up. At that time point, an IOP reduction
≥ 20% with no medications was achieved in nine out of 20
patients, to give a success rate of 45%. Beyond the one-year
visit, success rates fell (Table 2), consistent with the increased
use of antiglaucoma medications. We hypothesize that ultra-
structural changes in the TM or Schlemm’s canal could be
responsible for this increase in medications required. Our
complete success rate at one year (50%) was lower than the
other reported rates for two GTS-400 devices at one year.
Fea et al. [17] reported a 92.6% of complete success, while
Voskanyan et al. [15] reported 66%. Probable reasons for this
discrepancy have been analysed above.
Our findings indicated a highly acceptable safety profile,
with no adverse events or long-term complications related
to stent implant. No subjects experienced hypotony, endoph-
thalmitis, or sight-threatening complications associated with
more invasive surgery procedures. Mean visual acuity was
significantly improved at each follow-up visit. There was a
mild decrease inmean visual acuity beyond the one-year visit,
attributed mainly to PCO.
Our study has several limitations. The number of patients
was low and, being a long-term study, several patients were
lost to follow-up such that only slightly more than half
of the patients completed 60 months of follow-up. Being
uncontrolled, we could not determine the individual effects
of phacoemulsification or iStent placement on IOP and the
number of hypotensive drugs required.The cohort examined
was a heterogeneous group of subjects, with mild-moderate
primary open-angle or pseudoexfoliative glaucoma along
with OHT patients. Moreover, as reported above, these
patients were the first to receive the iStent GTS-400 at our
centre, meaning that, despite experience with the GTS-100
model, the surgeons were at an early learning stage with the
use of the new model, which could affect outcomes. Finally,
in seven patients (35%), only one iStent was confirmed
as functional [14]. This potential shortcoming could also
affect the IOP and medication use results [7, 12], although
nonsignificant differences were found.
5. Conclusions
To the best of our knowledge, this is the first study to assess
combined GTS-400 iStent implantation and phacoemulsifi-
cation surgery over a follow-up period longer than one year.
Significant reductions were achieved in IOP and number of
medications required aftermore than 47months of follow-up.
At the end of follow-up, 45% of the patients were medication-
free and all patients showed good visual outcomes with
no serious adverse events recorded. Our findings suggest
that iStent GTS-400 placement added to phacoemulsification
could be a long-term safe and effective treatment option
alternative for patients with both cataract andmild-moderate
open-angle glaucoma or OHT. These findings, nevertheless,
require confirmation in randomized controlled studies con-
ducted in large patient cohorts.
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